Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP +0.38%77 3-Year EBITDA Growth Rate is 26.20% as of Jun. 2026, which is 0% above its 10-year median of 26.10. GuruFocus rates LTS:0DRP with a GF Score™ of 77/100 and a GF Value™ of €2.62 (Fairly Valued). The stock has 3 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Biohit Oyj ranks better than 73.69% on this metric.
During the past 12 months, Biohit Oyj's average EBITDA Per Share Growth Rate was 18.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 26.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biohit Oyj was 65.20% per year. The lowest was -45.10% per year. And the median was 26.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biohit Oyj 3-Year EBITDA Growth Rate Related Terms
LTS:0DRP vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Biohit Oyj's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 26.20% mean?
Biohit Oyj (LTS:0DRP) has a 3-Year EBITDA Growth Rate of 26.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biohit Oyj and its competitors. This is near median its historical median of 26.10. According to the industry distribution chart, Biohit Oyj ranks #181 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Biohit Oyj's 3-Year EBITDA Growth Rate too high?
Biohit Oyj's current 3-Year EBITDA Growth Rate of 26.20% is near median its 10-year median of 26.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Biohit Oyj's value of 26.20% is 231.6% above this industry median. Based on the distribution chart, Biohit Oyj ranks #181 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #181 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Biohit Oyj in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Biohit Oyj's value of 26.20% is 231.6% above this benchmark. While the company's 10-year median is 26.10 vs. the industry median of 7.90, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current 3-Year EBITDA Growth Rate of 26.20% is 231.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current 3-Year EBITDA Growth Rate is 26.20%, which is near median its own 10-year median of 26.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.62, compared to a current price of €2.61 — trading 0.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 26.20%, which is near median its 10-year median of 26.10 and 231.6% above the Medical Devices & Instruments industry median of 7.90. Biohit Oyj's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current 3-Year EBITDA Growth Rate is 26.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.61 is trading 0.4% below its estimated GF Value™ of €2.62.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
3-Year EBITDA Growth Rate: 26.20% (near median its 10-year median of 26.10)
GF Value™: €2.62 vs. price of €2.61 (0.4% below fair value)
Industry Position: 231.6% above the Medical Devices & Instruments median (#181 of 688)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
77GF Score
Get the complete analysis for LTS:0DRP
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
